Parabilis Medicines, Inc. (PBLS) Live Share Price, Invest From India

Parabilis Medicines, Inc. Stock Performance

as on September 11, 2026 at 6:59 am IST

Day's Low
Day's High
$36.13
Day's Price Range
$38.57
$36.38
0.69%
Downside
6.02%
Upside
52 Week's Low
52 Week's High
52-Week Price Range
$36.38
100.00%
Downside
-100.00%
Upside

Parabilis Medicines, Inc. share price movements today

Previous Close: $38.76
Open: $38.57
Volume: 557.8K
Market Cap: $4.9B
Day's Low - High: $36.13 - $38.57

Parabilis Medicines, Inc. Historical Returns

1 Month Return: + 8.48 %
3 Month Return: + 22.66 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Parabilis Medicines, Inc. Stock Fundamentals & Key Indicators

Check Parabilis Medicines, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$4.9B

EPS (TTM)

-36.9

Dividend Yield

0.00%

PE Ratio (TTM)

-1.05

Industry PE ratio

-13.83

PEG Ratio

0.14931205298510125

Return On Equity TTM

-15.14%

Parabilis Medicines, Inc. Stock Valuation

Track how Parabilis Medicines, Inc. P/E has moved over time to understand its valuation trends.

Parabilis Medicines, Inc. in the last 2 years

Overview
Trends

Lowest (-0.24x)

December 31, 2024

Industry (-13.83x)

December 31, 2025

Today (-0.22x)

December 31, 2025

Highest (-0.22x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: -0.22x

Parabilis Medicines, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Parabilis Medicines, Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Parabilis Medicines, Inc.	StrongBuy	$4.9B	NA	-1.05	100.00%	NA
Revolution Medicines	BUY	$44.6B	614.61%	NA	0.00%	NA
Vertex Pharmaceuticals	BUY	$138.4B	181.2%	30.54	86.04%	NA
Moderna	BUY	$56.0B	-69.82%	-16.99	-12.57%	NA
Regeneron	BUY	$85.2B	24.16%	19.28	84.86%	45.660000000000004%

Analyst Recommendation on Parabilis Medicines, Inc. Stock

Based on 5 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 5 analysts, 100% of analysts recommend a 'BUY' rating for Parabilis Medicines, Inc.. Average target price of $40.67

Indian Investors' Interest in Parabilis Medicines, Inc. Stock

Search interest for Parabilis Medicines, Inc. Stock has increased by 22% in the last 30 days, reflecting an upward trend in search activity.

Time period: August 12, 2026 to September 11, 2026

Change:22% versus previous 30 day period

Parabilis Medicines, Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2026	Jun 2026
Total Revenue	-	0
Gross Profit	-	0
Operating Income	-47	-50
EBITDA	-44	-51
Interest Expense	0	0
Depreciation	0	0
Income Before Tax	-45	-52
Income Tax Expense	-	-
Net Income	-45	-52
Net Profit Margin	0.00%	100.00%

Parabilis Medicines, Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2024	Dec 2025
Total Revenue	-	-
Gross Profit	-	-
Operating Income	-126	-152
EBITDA	-114	-141
Interest Expense	1	1
Depreciation	2	2
Income Before Tax	-117	-145
Income Tax Expense	-	-
Net Income	-117	-145
Net Profit Margin	0.00%	0.00%

Parabilis Medicines, Inc. Quarterly Cash Flow

All numbers in Millions USD

	Mar 2026	Jun 2026
Net Income	-45	-52
Operating Cash Flow	-49	-3
Investing Cash Flow	0	-34
Financing Cash Flow	350	795
Change in Cash	301	758

Parabilis Medicines, Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2024	Dec 2025
Net Income	-117	-145
Operating Cash Flow	-103	-123
Investing Cash Flow	30	39
Financing Cash Flow	78	64
Change in Cash	4	-19

Global Institutional Holdings in Parabilis Medicines, Inc.

Funds	Holdings
Peter Kolchinsky	23.73%
Vanguard	1.98%
Andrew J.M. Spokes	1.94%
James E. Flynn	1.54%
Felix Baker	0.41%

See all

Insights on Parabilis Medicines, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 3 months, PBLS stock has moved up by 27.9%

About Parabilis Medicines, Inc.

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Organisation	Parabilis Medicines, Inc.
Headquarters	30 Acorn Park Drive, Cambridge, MA, United States, 02140
Industry	Biotechnology
CEO	Dr. Mathai Mammen M.D., Ph.D.
E-voting on shares	Click here to vote

Key Management of Parabilis Medicines, Inc.

Name	Title
Dr. Mathai Mammen M.D., Ph.D.	CEO, President, Treasurer & Chairman
Dr. Mohammed Fawzi Benzaghou M.D.	Chief Medical Officer
Ms. Kristen Stants	Chief People Officer
Dr. Jonathan Hurov Ph.D.	Executive Vice President of Discovery Biology
Ms. Marie Nguyen M.D.	Senior VP & Head of Clinical Development
Ms. Teresa L. Jurgensen J.D.	Executive VP, Secretary & General Counsel
Mr. John McGee Ph.D.	Scientific Co-Founder, Executive Vice President & Head of Platform
Mr. Thomas Rodolpho Kotarakos	Chief Financial Officer
Dr. Rohin Mhatre Ph.D.	Chief Technical Operations Officer
Dr. Markus Haeberlein MSc, Ph.D.	Executive Vice President of Discovery Science

FAQs

What is Parabilis Medicines, Inc. share price today?

Parabilis Medicines, Inc. share price today is $36.38 as on September 11, 2026 at 1:29 am IST at the close of the market. Parabilis Medicines, Inc. share today touched a day high of $38.57 and a low of $36.13.

What is the 52 week high and 52 week low for Parabilis Medicines, Inc. share?

Parabilis Medicines, Inc. share touched a 52 week high of $0.00 on January 1, 1970 and a 52 week low of $0.00 on January 1, 1970. Parabilis Medicines, Inc. stock price today i.e. September 11, 2026 at 1:29 am IST is closed at $36.38,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is Parabilis Medicines, Inc.'s market capitalisation today?

Parabilis Medicines, Inc. market capitalisation is $0.00T as on September 11, 2026 at 1:29 am IST.

How to invest in Parabilis Medicines, Inc. Stock (PBLS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Parabilis Medicines, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Parabilis Medicines, Inc. Shares that will get you 0.0412 shares as per Parabilis Medicines, Inc. share price of $36.38 per share as on September 11, 2026 at 1:29 am IST.

What is the minimum amount required to buy Parabilis Medicines, Inc. Stock (PBLS) from India?

Indian investors can start investing in Parabilis Medicines, Inc. (PBLS) shares with as little as ₹95.43 or $1 (as of September 11, 2026 at 7:40 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹954.30 in Parabilis Medicines, Inc. stock (as per the Rupee-Dollar exchange rate as on September 11, 2026 at 7:40 am IST). Based on Parabilis Medicines, Inc. share’s latest price of $36.38 as on September 11, 2026 at 1:29 am IST, you will get 0.2749 shares of Parabilis Medicines, Inc.. Learn more about fractional shares .